Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00426660 · ClinicalTrials.gov registry record · Phase 3
Expanded Access Program for Maraviroc At Multiple Centers
A Phase 3 study of HIV Infections, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,047
- Enrollment target
- 20
- Study locations
NCT00426660: Completed Phase 3 study of HIV Infections, sponsored by ViiV Healthcare.
NCT00426660 is a Phase 3 study of HIV Infections that has completed, run by ViiV Healthcare. The registered enrollment target is 1,047 participants, above the 444-participant average among 542 other HIV Infections trials with a reported enrollment target (136% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00426660, a Phase 3 study of HIV Infections, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,047 participants
- Enrollment target
- 20
- Study locations
Study Summary
To provide access to maraviroc to patients who have limited or no therapeutic treatment options and to collect more safety data in a broader patient population.
Primary Outcome
AEs as defined by the Division of AIDS (DAIDS) toxicity grading scale: Grade 3 = severe: interrupted usual daily activity and traditionally required systemic drug therapy or other treatment. Grade 4 = very severe: events that were unacceptable and intolerable or were irreversable or caused imminent danger of death. If same participant had more than 1 occurrence in the same preferred term event category, only the most severe (grade 4) occurrence was taken. Treatment-related = investigator assessm
Conditions Studied
Interventions
- DRUG maraviroc
Study Locations (20)
California
- Vista Medical - Beverly Hills
- AHF Research Center - Beverly Hills
- Orange County Center for Special Immunology - Fountain Valley
- Kaiser Permanente - Hayward
- Living Hope Clinical Trials - Long Beach
- AltaMed Health Services Corporation - Los Angeles
- Kaiser Permanente Medical Center - Los Angeles
- Robert Bolan, MD - Los Angeles
- Maternal-Child and Adolescent Clinic of Infectious Diseases and Virology - Los Angeles
- Peter J. Ruane, M.D. Inc. - Los Angeles
- Synergy Hematology-Oncology Associates - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- Erlmed Corp ABA Lim-Keith Muiltispecialty Clinic Inc. - Los Angeles
- Office of Anthony Mills, MD - Los Angeles
- Office of Dr. Salah Bibi, MD - Modesto
Alabama
- The University of Alabama - Birmingham
- Health Services Center - Hobson City
Arkansas
- Health for Life Clinic PLLC - Little Rock
- Thomas T Jefferson, MD - Little Rock
Arizona
- El Rio, Special Immunology Associates - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,047 participants |
| Start Date | 2007-02 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
What the finished NCT00426660 record still lists
NCT00426660 is an interventional study that assigns participants to a tested intervention. Its 1,047 participants enrollment target places it among the larger protocols in the corpus, above the 444-participant average among 542 other HIV Infections trials with a reported enrollment target (136% higher).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which maraviroc is the first listed.
NCT00426660 names 20 study sites across 4 states, led by California, Alabama, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00426660 about?
NCT00426660 is a clinical study titled "Expanded Access Program for Maraviroc At Multiple Centers". To provide access to maraviroc to patients who have limited or no therapeutic treatment options and to collect more safety data in a broader patient population.
What is the current status of trial NCT00426660?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,047 participants. The study started on 2007-02. Estimated completion is 2010-06.
What conditions does trial NCT00426660 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00426660?
The interventions under investigation include: maraviroc (DRUG).
Who is sponsoring clinical trial NCT00426660?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00426660 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00426660's enrollment target sits among peer trials
1,047 28th of 542 higher than 515 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06717347 · 1,046 participants · Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- NCT04505618 · 1,050 participants · NA
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
- NCT04511806 · 1,050 participants
Childhood Cancer Predisposition Study (CCPS)
- NCT05028972 · 1,050 participants · NA
Hearing Impairment, Strategies and Outcomes in VA Emergency Departments
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia